Cervical Cancer Diagnostic Testing Devices Sales

Cervical Cancer Diagnostic Testing Devices Sales Market Outlook

The global cervical cancer diagnostic testing devices market is projected to reach approximately USD 6.1 billion by 2035, growing at a compound annual growth rate (CAGR) of around 8.5% during the forecast period from 2025 to 2035. The increasing prevalence of cervical cancer and rising awareness regarding early detection are pivotal factors driving the growth of this market. Additionally, advancements in technology, along with the launch of innovative diagnostic solutions, are further enhancing the demand for cervical cancer diagnostic testing devices. Furthermore, government initiatives aimed at improving screening rates and healthcare infrastructure in developing regions are expected to contribute significantly to market expansion. With a growing focus on preventive healthcare and early diagnosis, the market for cervical cancer diagnostic testing devices is set to flourish in the coming years.

Growth Factor of the Market

The growth of the cervical cancer diagnostic testing devices market is primarily fueled by the increasing incidences of cervical cancer across the globe, which has underscored the necessity for effective screening and diagnostic solutions. In addition, heightened awareness campaigns regarding the importance of early detection have led to improved screening rates, further stimulating market growth. Moreover, technological advancements such as the integration of AI in diagnostic tools are enhancing the accuracy and efficiency of testing methods. The rising number of healthcare facilities and diagnostic laboratories, particularly in emerging markets, is also expected to serve as a catalyst for market expansion. Lastly, the ongoing research and development initiatives aimed at discovering novel diagnostic methods are anticipated to open new avenues for growth within the industry.

Key Highlights of the Market

• Significant growth potential is driven by the increasing incidence of cervical cancer worldwide.
• Technological advancements are improving the accuracy and efficiency of diagnostic testing.
• Government initiatives are aiming to improve screening rates, especially in developing regions.
• Growing awareness regarding women's health is leading to increased screening and testing.
• The market is seeing a rise in partnerships between companies and healthcare institutions for innovative solutions.

By Product Type

Pap Smear Tests:

Pap smear tests remain one of the most widely used methods for cervical cancer screening globally. The procedure involves collecting cells from the cervix and examining them for abnormalities that may indicate cancer or precancerous conditions. This test is favored for its cost-effectiveness and ease of administration, making it accessible in various healthcare settings. The increasing recommendation for routine Pap smears by healthcare professionals has significantly contributed to its market share. Additionally, the implementation of automated Pap testing systems is expected to enhance accuracy, further boosting its adoption.

HPV DNA Tests:

HPV DNA tests are emerging as a critical component in cervical cancer diagnostics, primarily due to their ability to detect high-risk strains of the human papillomavirus that are responsible for the majority of cervical cancer cases. These tests are often utilized in conjunction with Pap smears for comprehensive screening. The growing awareness about HPV as a causative factor for cervical cancer is propelling the demand for HPV DNA testing. Furthermore, advancements in molecular testing technologies are enhancing the sensitivity and specificity of HPV diagnostics, leading to a more significant market share.

Colposcopy:

Colposcopy is a diagnostic procedure used for closer examination of the cervix, vagina, and vulva after abnormal Pap smear results or positive HPV tests. This technique allows healthcare providers to identify precancerous lesions more accurately. The increasing number of women undergoing colposcopic evaluations is contributing to the growth of this segment. Furthermore, advancements in colposcopy technologies, such as the integration of digital imaging systems, are improving the visualization of cervical abnormalities, thereby enhancing diagnostic accuracy.

Cervical Biopsies:

Cervical biopsies involve the removal of a small sample of cervical tissue for laboratory analysis, used to confirm the presence of cancerous or precancerous cells. This method is typically employed when previous screening tests indicate potential abnormalities. The segment is expected to grow as more women are referred for biopsies due to the heightened awareness of cervical health. Additionally, technological improvements in biopsy techniques, including the development of less invasive methods, are likely to increase patient acceptance and procedure adoption.

Others:

The 'Others' category encompasses various emerging diagnostic tests and devices, such as liquid-based cytology and newer molecular diagnostic techniques. This segment is gaining traction, fueled by the increasing focus on alternative methods that offer improved accuracy and patient comfort. Innovations in this area are likely to proliferate as research advances, aiming to provide comprehensive screening solutions that cater to diverse patient needs. The growth of this segment will be essential in the overall market expansion, as the demand for diverse testing options increases.

By Application

Hospitals:

Hospitals play a pivotal role in the cervical cancer diagnostic testing market, serving as primary settings for comprehensive screening and diagnosis. With specialized departments dedicated to women's health, hospitals are equipped with advanced diagnostic devices and skilled professionals who conduct various tests, including Pap smears and HPV testing. The rising patient footfall in hospitals for routine check-ups and specialized care has increased the demand for cervical cancer diagnostic devices in this segment. Furthermore, hospitals are often at the forefront of implementing new technologies and treatment protocols, thereby influencing market dynamics significantly.

Clinics:

Clinics, including outpatient facilities and gynecological clinics, are crucial for cervical cancer screening and diagnostics, offering accessible services to women. The convenience of clinics allows for easier appointment scheduling and quicker turnaround times for test results. As awareness about cervical cancer screening grows, more women are opting for regular check-ups at clinics, resulting in an increase in demand for diagnostic testing devices within this segment. Additionally, clinics are increasingly adopting innovative technologies to enhance patient care, further driving the need for advanced diagnostic solutions.

Diagnostic Laboratories:

Diagnostic laboratories are central to the cervical cancer diagnostic testing market, providing crucial services in analyzing samples collected from patients. As the demand for accurate and timely results escalates, laboratories are investing in advanced diagnostic technologies, including molecular diagnostics and automated systems. The growth of the diagnostic laboratory segment is fueled by an increase in the number of testing facilities and the expansion of laboratory services to cater to a growing patient population. Moreover, collaborations between hospitals and diagnostic laboratories are facilitating an increase in testing volumes, enhancing the overall market growth.

Research Institutes:

Research institutes are essential for the development of innovative cervical cancer diagnostic technologies. They play a significant role in conducting studies, clinical trials, and developing new diagnostic methods aimed at improving detection rates and treatment outcomes. The investment in research and development activities is expected to drive growth in this segment, as these institutions aim to translate scientific discoveries into practical applications. Additionally, partnerships between research institutes and diagnostic device manufacturers are fostering innovation, thereby contributing positively to market dynamics.

Others:

The 'Others' category includes various non-traditional settings, such as mobile health clinics and community health organizations, which are increasingly participating in cervical cancer screening initiatives. These alternative applications are gaining traction as public health campaigns focus on increasing accessibility to diagnostic services, particularly in underserved areas. The growing emphasis on preventive healthcare and the integration of technology in community health initiatives are expected to drive demand in this segment. As more women gain access to screening through these channels, the overall market potential expands.

By Distribution Channel

Hospitals Pharmacies:

Hospitals pharmacies serve as vital distribution points for cervical cancer diagnostic testing devices, providing healthcare professionals with easy access to necessary tools for screening and treatment. The convenience of obtaining diagnostic tests in a hospital setting enhances patient care by streamlining the process of diagnosis and treatment. The growth of this segment is supported by the increasing number of women seeking cervical cancer screenings and the rising awareness of the importance of early detection. Furthermore, hospitals are increasingly stockpiling a variety of diagnostic devices, catering to diverse patient needs while ensuring efficient patient flow.

Online Sales:

Online sales have emerged as a significant distribution channel for cervical cancer diagnostic testing devices, particularly in the context of the growing e-commerce market. The convenience of purchasing diagnostic devices online has made it easier for healthcare providers and patients to obtain essential testing kits without the need for physical visits to stores. This segment is anticipated to experience substantial growth, driven by the increasing demand for home testing kits and self-sampling options. Moreover, online platforms often provide detailed product information and customer reviews, facilitating informed purchasing decisions.

Retail Pharmacies:

Retail pharmacies play an essential role in the distribution of cervical cancer diagnostic testing devices, particularly in providing over-the-counter testing kits and educational materials. The accessibility of these devices at retail locations increases awareness and encourages women to participate in regular screenings. As women become more proactive about their health, the demand for self-testing kits available in retail pharmacies is expected to rise. Furthermore, partnerships between pharmaceutical companies and retail chains are likely to improve the availability of these products, enhancing market growth.

Direct Sales:

Direct sales involve manufacturers selling cervical cancer diagnostic testing devices directly to healthcare providers, eliminating intermediaries and ensuring better pricing and supply chain management. This approach allows manufacturers to build strong relationships with their customers and respond quickly to market demands. The growth of this segment is driven by the increasing number of hospitals and diagnostic laboratories seeking specialized equipment directly from manufacturers. Furthermore, direct sales enable better support and training for healthcare professionals, enhancing the effective use of diagnostic devices.

Others:

The 'Others' category encompasses various alternative distribution channels, including partnerships with non-profit organizations and community health programs that facilitate access to cervical cancer diagnostic testing devices. These channels are becoming increasingly important as public health initiatives aim to increase screening rates, particularly in low-income and underserved populations. As awareness campaigns focus on the importance of early detection, these alternative channels will likely experience growth, contributing to overall market expansion.

By Technology

Immunohistochemistry:

Immunohistochemistry (IHC) is a laboratory technique that uses antibodies to detect specific antigens in tissue samples, making it a vital tool in cervical cancer diagnostics. This technology allows for the visualization of cellular abnormalities and helps in differentiating between various types of cervical lesions. The increasing adoption of IHC in clinical laboratories is driven by its ability to provide precise and rapid results, facilitating timely diagnoses. As more healthcare facilities recognize the value of IHC in cervical cancer detection, its market share is expected to grow significantly.

Molecular Diagnostics:

Molecular diagnostics involve the analysis of genetic material to identify the presence of disease, including cervical cancer. This technology has gained traction due to its high sensitivity and specificity, allowing for the detection of HPV and other molecular markers associated with cervical cancer. The increasing focus on personalized medicine and targeted therapies is propelling the demand for molecular diagnostic tests in cervical cancer screening. As healthcare providers seek accurate and reliable diagnostic methods, molecular diagnostics are likely to play an increasingly prominent role in the market.

Colposcopy:

Colposcopy, as previously mentioned, is a diagnostic procedure that enhances visualization of the cervix and surrounding tissues, enabling accurate assessment of cervical abnormalities. The integration of advanced colposcope technology, including digital and high-definition systems, is improving diagnostic accuracy and patient outcomes. As the importance of thorough cervical examinations becomes more recognized, the demand for colposcopy devices is expected to increase. Continued innovations in colposcopic technology will further bolster its position in the cervical cancer diagnostic device market.

HPV Testing:

HPV testing is a key technological advancement in cervical cancer diagnostics, specifically designed to detect high-risk strains of the human papillomavirus. Given the causal relationship between HPV and cervical cancer, this testing method has garnered significant attention. The growing trend towards routine HPV screenings, especially in combination with Pap smears, is expected to drive the market for HPV testing technologies. Furthermore, advancements in testing methodologies, such as liquid-based cytology and next-generation sequencing, are enhancing the overall sensitivity and specificity of HPV diagnostics, thereby promoting their adoption.

Others:

The 'Others' category includes various emerging technologies and methodologies utilized in cervical cancer diagnostics, such as liquid-based cytology and self-sampling kits. These innovative approaches are gaining popularity due to their potential to increase accessibility and patient comfort. As the healthcare landscape evolves and patient-centric models gain traction, the demand for diverse and user-friendly diagnostic options will likely drive growth in this segment. Continued investments in research and development are anticipated to yield new technologies that further enhance the capabilities of cervical cancer diagnostics.

By Region

North America dominates the cervical cancer diagnostic testing devices market, accounting for a significant share due to well-established healthcare infrastructure and high awareness levels regarding cervical cancer screening. The region's market is expected to grow at a CAGR of approximately 7.2% during the forecast period, driven by the increasing incidence of cervical cancer and the adoption of advanced diagnostic technologies. The United States, in particular, is witnessing a rise in government initiatives aimed at promoting regular screenings, which is further boosting market growth in this region. Additionally, the presence of leading diagnostic device manufacturers and a robust research environment contribute to North America's prominent position in the global market.

Europe also plays a crucial role in the cervical cancer diagnostic testing devices market, with countries like Germany, France, and the UK investing significantly in women's health initiatives. The European market is characterized by a growing emphasis on preventive healthcare and early diagnosis, leading to increased screening rates. The region's stringent regulations and quality standards for medical devices further enhance the credibility of diagnostic tests available in the market. As healthcare providers focus on improving cervical cancer screening programs, Europe's market is expected to grow steadily, albeit at a slightly lower CAGR compared to North America.

Opportunities

One of the most significant opportunities in the cervical cancer diagnostic testing devices market lies in the increasing demand for point-of-care testing solutions. The shift towards portable and user-friendly diagnostic devices enables healthcare providers to conduct screenings in various settings, including remote and underserved areas. As more women gain access to affordable and convenient testing options, the overall market potential expands. Furthermore, advancements in telemedicine and digital health technologies present opportunities to integrate cervical cancer screening into broader health management programs. This convergence of technology and healthcare can significantly increase participation rates in screening programs, particularly in regions with limited access to traditional healthcare facilities.

Additionally, there is a growing trend towards personalized medicine and tailored treatment approaches in cervical cancer diagnostics. This presents opportunities for companies to develop innovative diagnostic tests that cater to individual patient profiles and genetic predispositions. By focusing on personalized healthcare solutions, businesses can enhance patient outcomes while contributing to the overall improvement of cervical cancer screening programs. Moreover, collaborations between diagnostics manufacturers, healthcare providers, and research institutions can drive innovation and aid in the development of novel technologies that address existing gaps in cervical cancer diagnostics.

Threats

One of the primary threats to the cervical cancer diagnostic testing devices market is the increasing competition from alternative screening methods and diagnostic technologies. As the healthcare landscape evolves, new approaches may emerge that challenge the status quo of traditional testing methods, such as Pap smears and HPV testing. Additionally, the entry of new players into the market can lead to pricing pressures, affecting the profitability of established companies. The rapid pace of technological advancements also poses a threat, as organizations must continuously innovate to remain competitive. Consequently, failure to adapt to market changes could result in a loss of market share for existing manufacturers.

Another significant threat to the market is the regulatory challenges and compliance requirements associated with medical devices. The stringent regulations governing the approval and market entry of diagnostic devices can result in delays and increased costs for manufacturers. Additionally, the dynamic nature of healthcare policies, particularly regarding reimbursement for cervical cancer screening services, poses uncertainties that can impact market growth. Manufacturers must navigate these challenges effectively while ensuring that their products meet regulatory standards to maintain market viability.

Competitor Outlook

• Hologic, Inc.
• BD (Becton, Dickinson and Company)
• Roche Diagnostics
• Qiagen N.V.
• Abbott Laboratories
• Thermo Fisher Scientific Inc.
• Siemens Healthineers
• Genomma Lab Internacional, S.A.B. de C.V.
• Medtronic
• F. Hoffmann-La Roche Ltd.
• LabCorp
• Quest Diagnostics
• Cervical Cancer Prevention Program
• Bristol-Myers Squibb Company
• bioMérieux

The competitive landscape of the cervical cancer diagnostic testing devices market is characterized by a mixture of established players and emerging companies striving to capitalize on the growing demand for diagnostic solutions. Major players such as Hologic, Inc., Roche Diagnostics, and BD are continuously investing in research and development to enhance their product portfolios and maintain competitive advantage. These companies are also focusing on strategic partnerships and collaborations to expand their market presence and leverage complementary strengths. Additionally, mergers and acquisitions are becoming increasingly common as companies seek to integrate advanced technologies and gain access to new markets.

Hologic, Inc. is a leading player in the cervical cancer diagnostic testing market, known for its innovative solutions and commitment to women's health. The company offers a comprehensive range of products, including Pap tests, HPV tests, and advanced imaging systems. By focusing on technological advancements, Hologic aims to improve diagnostic accuracy and patient outcomes. This commitment to innovation has positioned Hologic as a key competitor in the market, driving its growth and expanding its reach in cervical cancer diagnostics.

Another prominent player, Roche Diagnostics, is recognized for its significant contributions to molecular diagnostics, particularly in the field of HPV testing. With a robust portfolio of diagnostic tests, Roche is at the forefront of advancements in cervical cancer screening. The company's focus on integrating digital health solutions with traditional diagnostic processes has enabled it to enhance the patient experience while ensuring precise results. Roche's commitment to research and development, along with collaborations with healthcare providers, strengthens its position in the cervical cancer diagnostic devices market.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 LabCorp
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Medtronic
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Qiagen N.V.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Hologic, Inc.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Quest Diagnostics
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Roche Diagnostics
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 bioMérieux
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Abbott Laboratories
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Siemens Healthineers
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 F. Hoffmann-La Roche Ltd.
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Bristol-Myers Squibb Company
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Thermo Fisher Scientific Inc.
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 BD (Becton, Dickinson and Company)
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Cervical Cancer Prevention Program
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Genomma Lab Internacional, S.A.B. de C.V.
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Cervical Cancer Diagnostic Testing Devices Sales Market, By Technology
    • 6.1.1 Immunohistochemistry
    • 6.1.2 Molecular Diagnostics
    • 6.1.3 Colposcopy
    • 6.1.4 HPV Testing
    • 6.1.5 Others
  • 6.2 Cervical Cancer Diagnostic Testing Devices Sales Market, By Application
    • 6.2.1 Hospitals
    • 6.2.2 Clinics
    • 6.2.3 Diagnostic Laboratories
    • 6.2.4 Research Institutes
    • 6.2.5 Others
  • 6.3 Cervical Cancer Diagnostic Testing Devices Sales Market, By Product Type
    • 6.3.1 Pap Smear Tests
    • 6.3.2 HPV DNA Tests
    • 6.3.3 Colposcopy
    • 6.3.4 Cervical Biopsies
    • 6.3.5 Others
  • 6.4 Cervical Cancer Diagnostic Testing Devices Sales Market, By Distribution Channel
    • 6.4.1 Hospitals Pharmacies
    • 6.4.2 Online Sales
    • 6.4.3 Retail Pharmacies
    • 6.4.4 Direct Sales
    • 6.4.5 Others

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Cervical Cancer Diagnostic Testing Devices Sales Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Cervical Cancer Diagnostic Testing Devices Sales market is categorized based on

By Product Type

• Pap Smear Tests
• HPV DNA Tests
• Colposcopy
• Cervical Biopsies
• Others

By Application

• Hospitals
• Clinics
• Diagnostic Laboratories
• Research Institutes
• Others

By Distribution Channel

• Hospitals Pharmacies
• Online Sales
• Retail Pharmacies
• Direct Sales
• Others

By Technology

• Immunohistochemistry
• Molecular Diagnostics
• Colposcopy
• HPV Testing
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Hologic, Inc.
• BD (Becton, Dickinson and Company)
• Roche Diagnostics
• Qiagen N.V.
• Abbott Laboratories
• Thermo Fisher Scientific Inc.
• Siemens Healthineers
• Genomma Lab Internacional, S.A.B. de C.V.
• Medtronic
• F. Hoffmann-La Roche Ltd.
• LabCorp
• Quest Diagnostics
• Cervical Cancer Prevention Program
• Bristol-Myers Squibb Company
• bioMérieux